Back to Journals » Biologics: Targets and Therapy » Volume 14

Galanin Receptors as Drug Target for Novel Antidepressants: Review

Authors Demsie DG, Altaye BM, Weldekidan E, Gebremedhin H, Alema NM, Tefera MM, Bantie AT

Received 1 December 2019

Accepted for publication 19 March 2020

Published 21 April 2020 Volume 2020:14 Pages 37—45

DOI https://doi.org/10.2147/BTT.S240715

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Doris Benbrook


Desalegn Getnet Demsie,1 Birhanetensay Masresha Altaye,2 Etsay Weldekidan,1 Hagazi Gebremedhin,1 Niguse Meles Alema,3 Mulugeta Mihrete Tefera,3 Abere Tilahun Bantie4

1College of Medicine and Health Sciences, Department of Pharmacy, Adigrat University, Adigrat, Ethiopia; 2College of Health Sciences, Debre Berhan University, Debre Berhan, Ethiopia; 3Bahir Dar Health Science College, Bahir Dar, Ethiopia; 4College of Medicine and Health Sciences, Department of Anesthesia, Adigrat University, Adigrat, Ethiopia

Correspondence: Desalegn Getnet Demsie Tel +251 937404956
Email desget361@gmail.com

Abstract: Galanin (GAL) is a 29-amino-acid neuropeptide that serves multiple physiological functions throughout the central and peripheral nervous system. Its role involves in a range of physiological and pathological functions including control of food intake, neuro-protection, neuronal regeneration, energy expenditure, reproduction, water balance, mood, nociception and various neuroendocrine functions. The use of currently available antidepressant drugs raises concerns regarding efficacy and onset of action; therefore, the need for antidepressants with novel mechanisms is increasing. Presently, various studies revealed the link between GAL and depression. Attenuation of depressive symptoms is achieved through inhibition of GalR1 and GalR3 and activation of GalR2. However, lack of receptor selectivity of ligands has limited the complete elucidation of effects of different receptors in depression-like behavior. Studies have suggested that GAL enhances the action of selective serotonin reuptake inhibitors (SSRIs) and promotes availability of transcription proteins. This review addresses the role of GAL, GAL receptors (GALRs) ligands including selective peptides, and the mechanism of ligand receptor interaction in attenuating depressive symptoms.

Keywords: Galanin (GAL), depression, Galanin (GAL) receptors

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]